CATX vs TECH · rev $2.2M vs P/E 65, rev $1.22B
Perspective Therapeutics Inc. (CATX) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Perspective Therapeutics Inc. (CATX) is a medical devices company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported CATX revenue for 2023-09-30 was $2.2M. Net income was -$10.4M. Revenue was up 4.6% from 2023-06-30 to 2023-09-30. CATX currently screens at market cap $280.6M.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
CATX currently screens at market cap $280.6M. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the CATX and TECH stock pages for the full models.
Not investment advice.